Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas
To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC). Forty patients with acromegaly, 40 with...
Gespeichert in:
| Veröffentlicht in: | Growth hormone & IGF research 2020-12, Vol.55, p.101356-101356, Article 101356 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101356 |
|---|---|
| container_issue | |
| container_start_page | 101356 |
| container_title | Growth hormone & IGF research |
| container_volume | 55 |
| creator | Ozkaya, Hande Mefkure Sahin, Serdar Korkmaz, Ozge Polat Durcan, Emre Sahin, Humeyra Rekali Celik, Emir Poyraz, Burc Cagri Kadioglu, Pinar |
| description | To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).
Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were evaluated using the revised version of the Minnesota Impulsive Disorders Interview (MIDI-R), Symptom Check List (SCL-90-R) questionnaire, Barratt Impulsiveness Scale (BIS-11), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
We detected ICD associated with DAs in two patients with acromegaly (5%) and three patients (7.5%) with prolactinoma. All patients' symptoms resolved after discontinuation of the drug. While the mean DA dose was higher in patients with acromegaly than prolactinomas (p 0.05). SCL-90 depression and interpersonal sensitivity subscale positivity was higher in patients with NFA than HCs. Patients with prolactinoma had higher obsession and interpersonal sensitivity positivity and those with NFA had higher somatization, interpersonal sensitivity, and depression positivity as compared to patients with acromegaly (p |
| doi_str_mv | 10.1016/j.ghir.2020.101356 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2448408082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1096637420300654</els_id><sourcerecordid>2448408082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-7f0cbeb1e493ff7e8f1244f2ce0755d1781500a79d0d53bfbd24fe20fb336f9d3</originalsourceid><addsrcrecordid>eNp9UctuFDEQtBCIhMAPcIh85DKbtj1PiQuKQoIUCQ5wtjx2e8ebGXuxPaD9BP4abzbkyMV2u6uq1VWEvGewYcDaq91mO7m44cAfP0TTviDnrBG84lz0L8sbhrZqRVefkTcp7QBgEH39mpwJAQyanp2TP99Uduhzor9dnqjSMSy4VfOBLm47ZepDpiNSlelUaow0uvRAbYjUhL1anC-9bfAu5cp5s2o01C37dU5IdfA5hpkal0I0GBPNk_LlCKX5OG1f2kpn58Oi0lvyyqrCe_d0X5Afn2--X99V919vv1x_uq90WTBXnQU94siwHoS1HfaW8bq2XCN0TWNY17MGQHWDAdOI0Y6G1xY52FGI1g5GXJAPJ90y_eeKKcvFJY3zrDyGNcmi1tfQQ88LlJ-gxZWUIlq5j25R8SAZyGMEciePEchjBPIUQSFdPumv44LmmfLP8wL4eAJg2fKXwyiTLhEU61xEnaUJ7n_6fwEqWZsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448408082</pqid></control><display><type>article</type><title>Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Ozkaya, Hande Mefkure ; Sahin, Serdar ; Korkmaz, Ozge Polat ; Durcan, Emre ; Sahin, Humeyra Rekali ; Celik, Emir ; Poyraz, Burc Cagri ; Kadioglu, Pinar</creator><creatorcontrib>Ozkaya, Hande Mefkure ; Sahin, Serdar ; Korkmaz, Ozge Polat ; Durcan, Emre ; Sahin, Humeyra Rekali ; Celik, Emir ; Poyraz, Burc Cagri ; Kadioglu, Pinar</creatorcontrib><description>To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).
Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were evaluated using the revised version of the Minnesota Impulsive Disorders Interview (MIDI-R), Symptom Check List (SCL-90-R) questionnaire, Barratt Impulsiveness Scale (BIS-11), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
We detected ICD associated with DAs in two patients with acromegaly (5%) and three patients (7.5%) with prolactinoma. All patients' symptoms resolved after discontinuation of the drug. While the mean DA dose was higher in patients with acromegaly than prolactinomas (p < 0.05), no difference was detected in terms of ICD prevalence between two groups (p > 0.05). SCL-90 depression and interpersonal sensitivity subscale positivity was higher in patients with NFA than HCs. Patients with prolactinoma had higher obsession and interpersonal sensitivity positivity and those with NFA had higher somatization, interpersonal sensitivity, and depression positivity as compared to patients with acromegaly (p < 0.05 for all).
Although DA dose was significantly higher in patients with acromegaly, there was no significant difference in the prevalence of DA-related ICD. The higher prevalence of positive screening in SCL-90 in patients with NFA in comparison to HCs supports the hypothesis that the presence of a pituitary adenoma per se might cause significant psychiatric symptoms.
•Although cabergoline is cheaper than first generation SSA, pasireotide, pegvisomant, it can cause psychiatric disorders•Endocrinologists should screen in terms of ICD during cabergoline treatment•High dose cabergoline don’t add an additional risk of ICD in patients with acromegaly as compared to prolactinomas</description><identifier>ISSN: 1096-6374</identifier><identifier>EISSN: 1532-2238</identifier><identifier>DOI: 10.1016/j.ghir.2020.101356</identifier><identifier>PMID: 33010581</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Acromegaly ; Dopamine agonist ; Impulse control disorder ; Prevalence</subject><ispartof>Growth hormone & IGF research, 2020-12, Vol.55, p.101356-101356, Article 101356</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-7f0cbeb1e493ff7e8f1244f2ce0755d1781500a79d0d53bfbd24fe20fb336f9d3</citedby><cites>FETCH-LOGICAL-c356t-7f0cbeb1e493ff7e8f1244f2ce0755d1781500a79d0d53bfbd24fe20fb336f9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ghir.2020.101356$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33010581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozkaya, Hande Mefkure</creatorcontrib><creatorcontrib>Sahin, Serdar</creatorcontrib><creatorcontrib>Korkmaz, Ozge Polat</creatorcontrib><creatorcontrib>Durcan, Emre</creatorcontrib><creatorcontrib>Sahin, Humeyra Rekali</creatorcontrib><creatorcontrib>Celik, Emir</creatorcontrib><creatorcontrib>Poyraz, Burc Cagri</creatorcontrib><creatorcontrib>Kadioglu, Pinar</creatorcontrib><title>Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas</title><title>Growth hormone & IGF research</title><addtitle>Growth Horm IGF Res</addtitle><description>To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).
Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were evaluated using the revised version of the Minnesota Impulsive Disorders Interview (MIDI-R), Symptom Check List (SCL-90-R) questionnaire, Barratt Impulsiveness Scale (BIS-11), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
We detected ICD associated with DAs in two patients with acromegaly (5%) and three patients (7.5%) with prolactinoma. All patients' symptoms resolved after discontinuation of the drug. While the mean DA dose was higher in patients with acromegaly than prolactinomas (p < 0.05), no difference was detected in terms of ICD prevalence between two groups (p > 0.05). SCL-90 depression and interpersonal sensitivity subscale positivity was higher in patients with NFA than HCs. Patients with prolactinoma had higher obsession and interpersonal sensitivity positivity and those with NFA had higher somatization, interpersonal sensitivity, and depression positivity as compared to patients with acromegaly (p < 0.05 for all).
Although DA dose was significantly higher in patients with acromegaly, there was no significant difference in the prevalence of DA-related ICD. The higher prevalence of positive screening in SCL-90 in patients with NFA in comparison to HCs supports the hypothesis that the presence of a pituitary adenoma per se might cause significant psychiatric symptoms.
•Although cabergoline is cheaper than first generation SSA, pasireotide, pegvisomant, it can cause psychiatric disorders•Endocrinologists should screen in terms of ICD during cabergoline treatment•High dose cabergoline don’t add an additional risk of ICD in patients with acromegaly as compared to prolactinomas</description><subject>Acromegaly</subject><subject>Dopamine agonist</subject><subject>Impulse control disorder</subject><subject>Prevalence</subject><issn>1096-6374</issn><issn>1532-2238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9UctuFDEQtBCIhMAPcIh85DKbtj1PiQuKQoIUCQ5wtjx2e8ebGXuxPaD9BP4abzbkyMV2u6uq1VWEvGewYcDaq91mO7m44cAfP0TTviDnrBG84lz0L8sbhrZqRVefkTcp7QBgEH39mpwJAQyanp2TP99Uduhzor9dnqjSMSy4VfOBLm47ZepDpiNSlelUaow0uvRAbYjUhL1anC-9bfAu5cp5s2o01C37dU5IdfA5hpkal0I0GBPNk_LlCKX5OG1f2kpn58Oi0lvyyqrCe_d0X5Afn2--X99V919vv1x_uq90WTBXnQU94siwHoS1HfaW8bq2XCN0TWNY17MGQHWDAdOI0Y6G1xY52FGI1g5GXJAPJ90y_eeKKcvFJY3zrDyGNcmi1tfQQ88LlJ-gxZWUIlq5j25R8SAZyGMEciePEchjBPIUQSFdPumv44LmmfLP8wL4eAJg2fKXwyiTLhEU61xEnaUJ7n_6fwEqWZsQ</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Ozkaya, Hande Mefkure</creator><creator>Sahin, Serdar</creator><creator>Korkmaz, Ozge Polat</creator><creator>Durcan, Emre</creator><creator>Sahin, Humeyra Rekali</creator><creator>Celik, Emir</creator><creator>Poyraz, Burc Cagri</creator><creator>Kadioglu, Pinar</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202012</creationdate><title>Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas</title><author>Ozkaya, Hande Mefkure ; Sahin, Serdar ; Korkmaz, Ozge Polat ; Durcan, Emre ; Sahin, Humeyra Rekali ; Celik, Emir ; Poyraz, Burc Cagri ; Kadioglu, Pinar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-7f0cbeb1e493ff7e8f1244f2ce0755d1781500a79d0d53bfbd24fe20fb336f9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acromegaly</topic><topic>Dopamine agonist</topic><topic>Impulse control disorder</topic><topic>Prevalence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozkaya, Hande Mefkure</creatorcontrib><creatorcontrib>Sahin, Serdar</creatorcontrib><creatorcontrib>Korkmaz, Ozge Polat</creatorcontrib><creatorcontrib>Durcan, Emre</creatorcontrib><creatorcontrib>Sahin, Humeyra Rekali</creatorcontrib><creatorcontrib>Celik, Emir</creatorcontrib><creatorcontrib>Poyraz, Burc Cagri</creatorcontrib><creatorcontrib>Kadioglu, Pinar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Growth hormone & IGF research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozkaya, Hande Mefkure</au><au>Sahin, Serdar</au><au>Korkmaz, Ozge Polat</au><au>Durcan, Emre</au><au>Sahin, Humeyra Rekali</au><au>Celik, Emir</au><au>Poyraz, Burc Cagri</au><au>Kadioglu, Pinar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas</atitle><jtitle>Growth hormone & IGF research</jtitle><addtitle>Growth Horm IGF Res</addtitle><date>2020-12</date><risdate>2020</risdate><volume>55</volume><spage>101356</spage><epage>101356</epage><pages>101356-101356</pages><artnum>101356</artnum><issn>1096-6374</issn><eissn>1532-2238</eissn><abstract>To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).
Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were evaluated using the revised version of the Minnesota Impulsive Disorders Interview (MIDI-R), Symptom Check List (SCL-90-R) questionnaire, Barratt Impulsiveness Scale (BIS-11), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
We detected ICD associated with DAs in two patients with acromegaly (5%) and three patients (7.5%) with prolactinoma. All patients' symptoms resolved after discontinuation of the drug. While the mean DA dose was higher in patients with acromegaly than prolactinomas (p < 0.05), no difference was detected in terms of ICD prevalence between two groups (p > 0.05). SCL-90 depression and interpersonal sensitivity subscale positivity was higher in patients with NFA than HCs. Patients with prolactinoma had higher obsession and interpersonal sensitivity positivity and those with NFA had higher somatization, interpersonal sensitivity, and depression positivity as compared to patients with acromegaly (p < 0.05 for all).
Although DA dose was significantly higher in patients with acromegaly, there was no significant difference in the prevalence of DA-related ICD. The higher prevalence of positive screening in SCL-90 in patients with NFA in comparison to HCs supports the hypothesis that the presence of a pituitary adenoma per se might cause significant psychiatric symptoms.
•Although cabergoline is cheaper than first generation SSA, pasireotide, pegvisomant, it can cause psychiatric disorders•Endocrinologists should screen in terms of ICD during cabergoline treatment•High dose cabergoline don’t add an additional risk of ICD in patients with acromegaly as compared to prolactinomas</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>33010581</pmid><doi>10.1016/j.ghir.2020.101356</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1096-6374 |
| ispartof | Growth hormone & IGF research, 2020-12, Vol.55, p.101356-101356, Article 101356 |
| issn | 1096-6374 1532-2238 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2448408082 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
| subjects | Acromegaly Dopamine agonist Impulse control disorder Prevalence |
| title | Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T16%3A29%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patients%20with%20acromegaly%20might%20not%20be%20at%20higher%20risk%20for%20dopamine%20agonist-induced%20impulse%20control%20disorders%20than%20those%20with%20prolactinomas&rft.jtitle=Growth%20hormone%20&%20IGF%20research&rft.au=Ozkaya,%20Hande%20Mefkure&rft.date=2020-12&rft.volume=55&rft.spage=101356&rft.epage=101356&rft.pages=101356-101356&rft.artnum=101356&rft.issn=1096-6374&rft.eissn=1532-2238&rft_id=info:doi/10.1016/j.ghir.2020.101356&rft_dat=%3Cproquest_cross%3E2448408082%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448408082&rft_id=info:pmid/33010581&rft_els_id=S1096637420300654&rfr_iscdi=true |